{"id":"naftopidil","rwe":[{"pmid":"41509089","year":"2026","title":"Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025.","finding":"","journal":"Arab journal of urology","studyType":"Clinical Study"},{"pmid":"41397657","year":"2026","title":"N-[3-(4-(2-methoxyphenyl) piperazine-1-yl) propyl]-heteroaromatic carboxamide as selective α(1A/1D)-adrenoceptor antagonists: SAR study and metabolic stability evaluation.","finding":"","journal":"Bioorganic & medicinal chemistry letters","studyType":"Clinical Study"},{"pmid":"41346266","year":"2025","title":"Silodosin in treating men With BPH-associated lower urinary tract Symptoms: A systematic review and network meta-analysis.","finding":"","journal":"International journal of surgery (London, England)","studyType":"Clinical Study"},{"pmid":"39856707","year":"2025","title":"Targeting UGT2B15 and NR1H4 interaction: a novel therapeutic strategy for polycystic ovary syndrome using naftopidil enantiomers.","finding":"","journal":"Journal of ovarian research","studyType":"Clinical Study"},{"pmid":"39623360","year":"2024","title":"Association between alpha blocker use and the risk of fractures in patients with chronic kidney disease: a cohort study.","finding":"","journal":"BMC nephrology","studyType":"Clinical Study"}],"tags":[{"label":"naftopidil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-1D adrenergic receptor","category":"target"},{"label":"ADRA1D","category":"gene"},{"label":"ADRA1A","category":"gene"},{"label":"ADRA1B","category":"gene"},{"label":"Active","category":"status"},{"label":"Benign prostatic hyperplasia","category":"indication"},{"label":"Asahi Kasei","category":"company"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Platelet Aggregation Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":71.958,"date":"","count":35,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=72)"},{"llr":69.63,"date":"","count":28,"signal":"Urinary retention","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=70)"},{"llr":54.738,"date":"","count":22,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=55)"},{"llr":40.255,"date":"","count":20,"signal":"Pneumonia aspiration","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=40)"},{"llr":36.409,"date":"","count":28,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=36)"},{"llr":36.302,"date":"","count":19,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=36)"},{"llr":32.582,"date":"","count":14,"signal":"Prostate cancer","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=33)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Asahi Kasei","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NAFTOPIDIL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:07:55.514378+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:08:00.765921+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAFTOPIDIL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:08:01.144036+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1593765/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:08:01.919693+00:00"}},"allNames":"flivas","offLabel":[],"synonyms":["BM-15275","KT-611","naftopidil","avishot","flivas","naftopil","naftopidil hydrochloride","naftopidil dihydrochloride","naftopidil HCl"],"timeline":[{"date":"1998-12-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Asahi Kasei)"}],"approvals":[{"date":"1998-12-25","orphan":false,"company":"Asahi Kasei","regulator":"PMDA"}],"brandName":"Flivas","ecosystem":[{"indication":"Benign prostatic hyperplasia","otherDrugs":[{"name":"alfuzosin","slug":"alfuzosin","company":"Covis Pharma Sarl"},{"name":"doxazosin","slug":"doxazosin","company":"Pfizer"},{"name":"dutasteride","slug":"dutasteride","company":"Glaxosmithkline"},{"name":"finasteride","slug":"finasteride","company":"Merck"}],"globalPrevalence":null}],"mechanism":{"target":"Alpha-1D adrenergic receptor","targets":[{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"ADRA1B","source":"DrugCentral","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor"}],"modality":"Small Molecule","drugClass":"naftopidil","explanation":"","oneSentence":"","technicalDetail":"Naftopidil selectively antagonizes the alpha-1D adrenergic receptor, leading to relaxation of smooth muscle in the prostate and bladder neck, thereby improving urinary flow and reducing symptoms of benign prostatic hyperplasia."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1873","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NAFTOPIDIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAFTOPIDIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:53:14.118839","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:08:03.520467+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dopamine","drugSlug":"dopamine","fdaApproval":"1974-02-25","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"epinephrine","drugSlug":"epinephrine","fdaApproval":"1948-11-19","patentExpiry":"Oct 20, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"isoprenaline","drugSlug":"isoprenaline","fdaApproval":"1956-03-09","relationship":"same-target"},{"drugName":"norepinephrine","drugSlug":"norepinephrine","fdaApproval":"1950-07-13","patentExpiry":"Mar 8, 2041","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"propranolol","drugSlug":"propranolol","fdaApproval":"1967-11-13","patentExpiry":"Oct 16, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"sotalol","drugSlug":"sotalol","fdaApproval":"1992-10-30","patentExpiry":"Nov 19, 2034","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"naftopidil","indications":{"approved":[{"name":"Benign prostatic hyperplasia","source":"DrugCentral","snomedId":266569009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dopamine","brandName":"dopamine","genericName":"dopamine","approvalYear":"1974","relationship":"same-target"},{"drugId":"epinephrine","brandName":"epinephrine","genericName":"epinephrine","approvalYear":"1948","relationship":"same-target"},{"drugId":"isoprenaline","brandName":"isoprenaline","genericName":"isoprenaline","approvalYear":"1956","relationship":"same-target"},{"drugId":"norepinephrine","brandName":"norepinephrine","genericName":"norepinephrine","approvalYear":"1950","relationship":"same-target"},{"drugId":"propranolol","brandName":"propranolol","genericName":"propranolol","approvalYear":"1967","relationship":"same-target"},{"drugId":"sotalol","brandName":"sotalol","genericName":"sotalol","approvalYear":"1992","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT01203371","phase":"PHASE3","title":"Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS","status":"WITHDRAWN","sponsor":"Apsen Farmaceutica S.A.","startDate":"2011-01-01","conditions":["Hyperplasia"],"enrollment":0,"completionDate":"2012-01-01"},{"nctId":"NCT02034604","phase":"PHASE4","title":"Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2013-12","conditions":["Neurogenic Lower Urinary Tract Dysfunction"],"enrollment":194,"completionDate":"2017-08"},{"nctId":"NCT01952314","phase":"PHASE3","title":"Medical Expulsive Therapy for Ureter Stone Using Naftopidil","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-05","conditions":["Ureter Stones"],"enrollment":150,"completionDate":"2015-08"},{"nctId":"NCT01959074","phase":"PHASE3","title":"The Effect of Naftopidil for the Double-J Stent Discomfort","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-05","conditions":["Disorder of Urinary Stent"],"enrollment":100,"completionDate":"2015-06"},{"nctId":"NCT00967772","phase":"PHASE1","title":"The Safety/Tolerability and Pharmacokinetics (PKs) of Naftopidil in Korean Healthy Male Volunteers","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2009-09","conditions":["Healthy"],"enrollment":16,"completionDate":"2010-03"},{"nctId":"NCT02011737","phase":"PHASE4","title":"Naftopidil 75mg for Improving Clearance of Urinary Stones","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2014-02","conditions":["Kidney Calculi","Ureter Calculi"],"enrollment":130,"completionDate":"2015-04"},{"nctId":"NCT01922375","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2011-12","conditions":["Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia"],"enrollment":411,"completionDate":"2012-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"R9PHW59SFN","CHEBI":"CHEBI:31891","INN_ID":"5589","UMLSCUI":"C0083701","chemblId":"CHEMBL1593765","ChEMBL_ID":"CHEMBL142635","KEGG_DRUG":"D01674","DRUGBANK_ID":"DB12092","PUBCHEM_CID":"4418","SECONDARY_CAS_RN":"57149-08-3","MESH_SUPPLEMENTAL_RECORD_UI":"C064357"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Asahi Kasei","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"3.3 hours","clearance":"11.0 mL/min/kg","bioavailability":"18%","fractionUnbound":"0.008%"},"publicationCount":310,"therapeuticAreas":["Urology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026","pmid":"41509089","title":"Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025.","journal":"Arab journal of urology"},{"date":"2026 Apr","pmid":"41397657","title":"N-[3-(4-(2-methoxyphenyl) piperazine-1-yl) propyl]-heteroaromatic carboxamide as selective α(1A/1D)-adrenoceptor antagonists: SAR study and metabolic stability evaluation.","journal":"Bioorganic & medicinal chemistry letters"},{"date":"2025 Dec 8","pmid":"41346266","title":"Silodosin in treating men With BPH-associated lower urinary tract Symptoms: A systematic review and network meta-analysis.","journal":"International journal of surgery (London, England)"},{"date":"2025 Jan 24","pmid":"39856707","title":"Targeting UGT2B15 and NR1H4 interaction: a novel therapeutic strategy for polycystic ovary syndrome using naftopidil enantiomers.","journal":"Journal of ovarian research"},{"date":"2024 Dec 2","pmid":"39623360","title":"Association between alpha blocker use and the risk of fractures in patients with chronic kidney disease: a cohort study.","journal":"BMC nephrology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Asahi Kasei","companyId":"asahi-kasei","modality":"Small molecule","firstApprovalDate":"1999","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"1998-12-25T00:00:00.000Z","mah":"Asahi Kasei","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:08:03.520467+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}